Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 7,439 Shares of Company Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Huda Zoghbi sold 7,439 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,652,693.38. This trade represents a 81.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $902.90 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $591.52 and a 12 month high of $991.73. The stock has a 50 day moving average of $802.45 and a two-hundred day moving average of $741.95. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The firm has a market cap of $92.96 billion, a P/E ratio of 19.94, a price-to-earnings-growth ratio of 1.38 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.83 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 51.86 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on REGN shares. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price for the company in a research report on Thursday, October 1st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Truist Financial lifted their target price on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a research report on Monday. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $898.97.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is advancing ALN-CIDEB into a Phase 3 study for liver disease, a step forward for its development pipeline. ALN-CIDEB Phase 3 study
• Positive Sentiment: Recent coverage cited solid earnings-estimate revisions as a possible support for further gains. The company’s latest reported quarter also beat analyst expectations for earnings and revenue, reinforcing its recent fundamental momentum. Earnings estimate revisions
• Neutral Sentiment: Regeneron joined the Mary Tyler Moore Vision Initiative consortium as a founding member. The collaboration connects the company with a vision-research effort, but no near-term financial impact was disclosed. Vision initiative consortium announcement
• Negative Sentiment: Multiple insider sales may be weighing on sentiment after the stock’s recent run-up. Director Huda Zoghbi sold 7,439 shares, reducing her holding by about 81%; EVP Joseph Larosa sold 4,466 shares, while director Christine Poon sold 7,830 shares. Such sales are not necessarily signals about company prospects, but the cluster may add to near-term caution. Zoghbi SEC filing Larosa SEC filing Poon SEC filing

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. CENTRAL TRUST Co grew its stake in shares of Regeneron Pharmaceuticals by 2.5% during the 3rd quarter. CENTRAL TRUST Co now owns 1,480 shares of the biopharmaceutical company’s stock worth $1,122,000 after purchasing an additional 36 shares during the period. Bingham Private Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 3.7% during the 3rd quarter. Bingham Private Wealth LLC now owns 473 shares of the biopharmaceutical company’s stock valued at $359,000 after acquiring an additional 17 shares during the period. Maryland State Retirement & Pension System lifted its position in shares of Regeneron Pharmaceuticals by 9.4% during the 3rd quarter. Maryland State Retirement & Pension System now owns 6,038 shares of the biopharmaceutical company’s stock valued at $4,578,000 after acquiring an additional 520 shares during the period. Joel Isaacson & Co. LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.0% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 3,129 shares of the biopharmaceutical company’s stock worth $2,373,000 after acquiring an additional 62 shares in the last quarter. Finally, Jacobi Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Jacobi Capital Management LLC now owns 1,695 shares of the biopharmaceutical company’s stock worth $1,285,000 after acquiring an additional 22 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.